Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H31NO2.ClH |
| Molecular Weight | 353.927 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCOC(=O)C(C1CCCCC1)C2=CC=CC=C2
InChI
InChIKey=WIELVDXKOYPANK-UHFFFAOYSA-N
InChI=1S/C20H31NO2.ClH/c1-3-21(4-2)15-16-23-20(22)19(17-11-7-5-8-12-17)18-13-9-6-10-14-18;/h5,7-8,11-12,18-19H,3-4,6,9-10,13-16H2,1-2H3;1H
Drofenine, product name Spasmo-Cibalgin (Novartis, Oman), is an antispasmodic/anticholinergic agent used for relaxing smooth muscle, treating dysmenorrhea, and relieving pain in the gastrointestinal tract, biliary passages, and urogenital tract. The possible therapeutic effect of drofenine is proposed by its activation of transient receptor potential vanilloid-3 (TRPV3), a member of the TRPV subfamily of TRP ion channels.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q8NET8 Gene ID: 162514.0 Gene Symbol: TRPV3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25089200 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Spasmo Cibalgin Approved UseUnknown |
|||
| Primary | Spasmo Cibalgin Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Drofenine: A 2-APB Analogue with Greater Selectivity for Human TRPV3. | 2014-10 |
|
| Inhibition effects of benactyzine and drofenine on human serum butyrylcholinesterase. | 2001-02-01 |
|
| Simultaneous determination of hydrochloride salts of adiphenine, diphenhydramine, ethyldiphenacetate, drofenine and promazine by ion-pair HPLC. | 1983-08 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ndrugs.com/?s=spasmo%20cibalgin
tablet
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25089200
Drofenine, was selective for TRPV3 in that activation of TRPA1, M8, V1, V2, and V4, which are known to be activated by the TRPV3 agonists 2-APB and/or carvacrol, was not observed at concentrations up to 1 mmol/L. A detectable change in TRPV3 activity was observed at concentrations as low as 30 μmol/L and increased in a concentration-dependent manner. At concentrations greater than 500 μmol/L, calcium flux exhibited some evidence of TRPV3 independence based on small and comparable responses in both native HEK-293 cells and other TRP channel overexpressing cell lines. The maximum change in cytosolic calcium (ΔF) for drofenine (EC50 = 207 μmol/L) was comparable to the known TRPV3 agonists 2-APB (EC50 = 78 μmol/L) and carvacrol (EC50 = 438 μmol/L).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
289372
Created by
admin on Mon Mar 31 18:39:20 GMT 2025 , Edited by admin on Mon Mar 31 18:39:20 GMT 2025
|
PRIMARY | RxNorm | ||
|
m4764
Created by
admin on Mon Mar 31 18:39:20 GMT 2025 , Edited by admin on Mon Mar 31 18:39:20 GMT 2025
|
PRIMARY | Merck Index | ||
|
42559
Created by
admin on Mon Mar 31 18:39:20 GMT 2025 , Edited by admin on Mon Mar 31 18:39:20 GMT 2025
|
PRIMARY | |||
|
MVB31OPW05
Created by
admin on Mon Mar 31 18:39:20 GMT 2025 , Edited by admin on Mon Mar 31 18:39:20 GMT 2025
|
PRIMARY | |||
|
DTXSID3045859
Created by
admin on Mon Mar 31 18:39:20 GMT 2025 , Edited by admin on Mon Mar 31 18:39:20 GMT 2025
|
PRIMARY | |||
|
92806
Created by
admin on Mon Mar 31 18:39:20 GMT 2025 , Edited by admin on Mon Mar 31 18:39:20 GMT 2025
|
PRIMARY | |||
|
100000087736
Created by
admin on Mon Mar 31 18:39:20 GMT 2025 , Edited by admin on Mon Mar 31 18:39:20 GMT 2025
|
PRIMARY | |||
|
208-954-1
Created by
admin on Mon Mar 31 18:39:20 GMT 2025 , Edited by admin on Mon Mar 31 18:39:20 GMT 2025
|
PRIMARY | |||
|
548-66-3
Created by
admin on Mon Mar 31 18:39:20 GMT 2025 , Edited by admin on Mon Mar 31 18:39:20 GMT 2025
|
PRIMARY | |||
|
C007183
Created by
admin on Mon Mar 31 18:39:20 GMT 2025 , Edited by admin on Mon Mar 31 18:39:20 GMT 2025
|
PRIMARY | |||
|
SUB01838MIG
Created by
admin on Mon Mar 31 18:39:20 GMT 2025 , Edited by admin on Mon Mar 31 18:39:20 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD